The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome (Q34248518)

31 July 2017

title

The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome (English)

1 reference

31 July 2017

main subject

irritable bowel syndrome

1 reference

Mark Pimentel

1 reference

Evangelos J Giamarellos-Bourboulis

31 July 2017

object named as

Evangelos J Giamarellos-Bourboulis

1 reference

31 July 2017

Emmannouil Pyleris

1 reference

31 July 2017

Dimitrios Tzivras

1 reference

31 July 2017

Vassilios Koussoulas

1 reference

31 July 2017

Charalambos Barbatzas

1 reference

31 July 2017

publication date

20 January 2012

1 reference

Digestive Diseases and Sciences

31 July 2017

published in

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

1321-1329

1 reference

Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

The pathogenesis of gastrointestinal bacterial overgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Bacterial overgrowth as a cause of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Prevalence of cardiovascular risk factors and the metabolic syndrome in middle-aged men and women in Gothenburg, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Diagnosis of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome: Frequency and predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Tropical sprue is associated with contamination of small bowel with aerobic bacteria and reversible prolongation of orocecal transit time

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2033-7

Abnormal breath testing in IBS: a meta-analysis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22262197

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

High dosage rifaximin for the treatment of small intestinal bacterial overgrowth

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22262197

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10620-012-2033-7

1 reference

Dimensions Publication ID

31 July 2017

1022361939

0 references

1 reference